Study of REGN13335 in Adult Participants With Pulmonary Arterial Hypertension (PAH) (NCT07318597)
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamic Effects of REGN13335, an Anti-PDGF-B Monoclonal Antibody, in Adults With Pulmonary Arterial Hypertension
🩺 Plain-English Summary (8th-Grade Level)
This study is researching an experimental drug called REGN13335. The study is focused on participants with Pulmonary Arterial Hypertension (PAH). The aim of the study is to see how safe and effective REGN13335 is in participants with PAH who are taking other PAH medicines. The study is looking at several other research questions, including: * What side effects may happen from taking REGN13335 * How much REGN13335 is in the blood at different times * Whether the body makes antibodies against REGN13335 (which could make REGN13335 less effective or could lead to side effects)
Who can join: Review the eligibility criteria below.
Location: University of Colorado Denver — Aurora, Colorado
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (27 Sites)
Showing the first 25 of 27 sites.
- University of Colorado Denver — Aurora, Colorado
- Tufts Medical Center — Boston, Massachusetts
- Mater Misericordiae Ltd — South Brisbane, Queensland
- Royal Hobart Hospital — Hobart, Tasmania
- UZ Leuven — Leuven, Vlaams-Brabant
- H.U.B. Erasme Hospital — Brussels,
- Hopital Bicetre — Le Kremlin-Bicêtre,
- Universitatsklinikum Halle — Halle, Saxony-Anhalt
- Clinic of University Greifswald — Greifswald,
- Universitatsmedizin Mainz — Mainz,
- P. Stradins Clinical University hospital — Riga,
- University Clinical Hospital in Poznan - Early Phase Unit — Poznan, Greater Poland Voivodeship
- University Hospital in Bialystok — Bialystok, Podlaskie Voivodeship
- Oddzial Kardiologiczny — Lodz, Łódź Voivodeship
- Gachon University Gil Medical Center — Namdong-gu, Incheon
- Asan Medical Center — Seoul, Songpa-gu
- Seoul National University Hospital — Seoul,
- Severance Hospital — Seoul,
- Samsung Medical Center — Seoul,
- Hospital Vall d'Hebron — Barcelona, Catalonia
- Hospital Universitario Costa del Sol — Marbella, Malaga
- Hospital Clinic, Barcelona — Barcelona,
- University hospital 12 de octubre — Madrid,
- University Hospital Salamanca — Salamanca,
- Hospital Universitario De Toledo — Toledo,
📞 Contact the Study Coordinator
Phone: (844) 734-6643
Email: clinicaltrials@regeneron.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Pulmonary Arterial Hypertension (PAH)
- A Study of Inhaled Treprostinil (LIQ861) in Adults With Pulmonary Arterial Hypertension Transitioning From Oral Selexipag — Columbus, Georgia
- Tiprelestat Versus Placebo When Added to Standard of Care for the Treatment of Pulmonary Arterial Hypertension (PAH) — Tucson, Arizona
- Reverse Remodeling of the Pulmonary Vasculature: a Longitudinal, Investigational Study of the Effects of Sotatercept. — Tucson, Arizona
- PAH Exercise Study — Seattle, Washington
- A Study Evaluating the Safety and Tolerability of Artesunate in Patients With Pulmonary Arterial Hypertension — Stanford, California
Explore by condition: All Pulmonary Arterial Hypertension (PAH) clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.